financetom
Business
financetom
/
Business
/
Graco Q2 Adjusted Earnings Rise, Net Sales Decline
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Graco Q2 Adjusted Earnings Rise, Net Sales Decline
Jul 24, 2024 2:19 PM

04:56 PM EDT, 07/24/2024 (MT Newswires) -- Graco ( GGG ) reported Q2 adjusted earnings late Wednesday of $0.77 per diluted share, up from $0.75 a year earlier.

Analysts polled by Capital IQ expected $0.76.

Net sales in the three months ended June 28 fell to $553.2 million from $559.6 million a year earlier.

Analysts surveyed by Capital IQ expected $562.3 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
A Trump presidency to pose mostly bearish risks for oil, Citi says
A Trump presidency to pose mostly bearish risks for oil, Citi says
Jul 25, 2024
(Reuters) - A Donald Trump presidency could be net bearish for oil prices due to a combination of factors including tariffs and oil-friendly policies, and pushing the Organization of the Petroleum Exporting Countries and allies (OPEC+) to release more oil into the market, Citi said in a research note on Thursday. Trump could roll back environmental policies, though broadly overturning...
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise
Jul 25, 2024
Thursday, Chemomab Therapeutics Ltd ( CMMB ). released topline results from the Phase 2 SPRING trial assessing its monoclonal antibody, CM-101, in patients with primary sclerosing cholangitis (PSC). Treatment with CM-101 achieved its primary endpoint of safety and tolerability. It demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects across various disease-related secondary efficacy endpoints, including statistically significant improvement in liver stiffness. CM-101...
AC Immune Shares Surge After Active-Immunotherapy Candidate Gets FDA Fast Track Designation for Alzheimer's Disease
AC Immune Shares Surge After Active-Immunotherapy Candidate Gets FDA Fast Track Designation for Alzheimer's Disease
Jul 25, 2024
01:58 PM EDT, 07/25/2024 (MT Newswires) -- AC Immune ( ACIU ) shares surged more than 12% in recent trading after the company said Thursday that its active-immunotherapy candidate ACI-35.030 has received fast track designation from the US Food and Drug Administration for Alzheimer's disease. The company said ACI-35.030, now called JNJ-2056, is being developed with Johnson & Johnson's (...
GM's Cruise looks to start charging for robotaxi rides next year, Bloomberg News reports
GM's Cruise looks to start charging for robotaxi rides next year, Bloomberg News reports
Jul 25, 2024
(Reuters) -General Motors' ( GM ) self-driving technology unit, Cruise, aims to return to running fully autonomous rides later this year and charge fares by early 2025, Bloomberg News reported on Thursday, citing people familiar with the matter. The division had said earlier this week it would focus on developing a next-generation Chevrolet Bolt car instead of a planned Origin...
Copyright 2023-2026 - www.financetom.com All Rights Reserved